Tag : biologic therapy

Neurology

Twelve Medical Groups Oppose UHC Copay Accumulator Program

Newsemia
In an Oct. 7 letter to UHC, the 12 groups acknowledged that the drugs targeted by the accumulator policy are expensive. "However, they are also...
Neurology

CGRPs Promising for Prevention of Chronic Cluster Headache

Newsemia
Treatment with CGRP monoclonal antibodies may reduce the frequency of chronic cluster headache attacks in patients with an inadequate response to other preventive medications, new...
Neurology

Optimal Dose of Fingolimod for Multiple Sclerosis Confirmed

Newsemia
The 0.5-mg dose of fingolimod provides a greater reduction in annualized relapse rate vs both the 0.25-mg dose of fingolimod and the 20-mg dose of...
Neurology

'Startling' Decline in BP Control Among American Adults

Newsemia
After decades of improvements in blood pressure control, the past few years have seen declining trends, possibly owing to the introduction of more relaxed targets...
Neurology

In MS, Serious AEs More Common in Rituximab vs Ocrelizumab

Newsemia
Medscape Medical News Source link...
Neurology

Lowering Rituximab Dose in Patients With MS Safe, Effective

Newsemia
A new study has found that reducing rituximab dosage from 1,000 mg every 6 months to 500 mg every 6 months is a safe and...
Neurology

TNF Inhibitors Linked to Inflammatory CNS Events

Newsemia
Use of tumor necrosis factor inhibitors in patients with autoimmune diseases may increase risk for inflammatory demyelinating and non-demyelinating central nervous system events, new data...
Neurology

FDA OKs Satralizumab (Enspryng) for NMOSD

Newsemia
Satralizumab is a humanized monoclonal antibody that inhibits interleukin-6 receptor activity, believed to play a key role in the inflammation associated with NMOSD. FDA Approvals...
Latest News

Cancer Patients Report Delays in Treatment Because of COVID-19

Newsemia
A survey by the American Cancer Society shows that cancer patients have experienced delays in treatment, with some treatments not being rescheduled, in this COVID-19...
Latest News

Case Fatality Rate for COVID-19 Near 1.4%, Increases With Age

Newsemia
The case fatality rate among persons aged 80 years or older is close to 8%, authors of new study estimate. Source link...
Latest News

Novel Coronavirus May Be Transmitted via FMT, FDA Warns

Newsemia
The FDA advises that additional safety measures be taken for fecal microbiota transplants after recent studies found evidence of SARS-CoV-2 virus in the stool of...
Latest News

Italian Oncologist's Cautionary Advice on COVID-19 for US Centers

Newsemia
Marina Garassino, MD, chief of the Medical Thoracic Oncology Unit at the Istituto Nazionale dei Tumori in Milan, Italy, talks about her experience during Italy’s...
Neurology

Maybe Memorizing the Krebs Cycle Was Worthwhile After All

Newsemia
Mitochondrial disorders are often difficult to diagnose and treat due to their multisystem nature. As scientists better understand mitochondrial function, effective treatments are beginning to...
Neurology

Levetiracetam Oral Solution Recalled in US

Newsemia
Lannett Company has recalled two lots of the anticonvulsant because of microbial contamination, which was identified during an evaluation of a raw material used to...
Neurology

SUNFISH: Risdiplam Meets Primary Endpoint in SMA

Newsemia
Risdiplam, an oral investigational agent designed to increase and sustain SMN protein levels of patients with spinal muscular atrophy (SMA), met the primary endpoint in...
Neurology

FDA Approves Botox for Lower-Limb Spasticity in Children

Newsemia
The FDA has approved Botox to ease lower-limb spasticity in children and adolescents aged 2 to 17 years, excluding spasticity caused by cerebral palsy. FDA...
AI/ML

Artificial Intelligence Rivals Experts in Diagnosing Brain Bleeds – Medscape

Newsemia
Artificial Intelligence Rivals Experts in Diagnosing Brain Bleeds  Medscape Source link...
Neurology

Fremanezumab May Reduce Attacks in Tough-to-Treat Migraine

Newsemia
The CGRP-targeting migraine-prevention drug fremanezumab is safe and effective in reducing migraines for patients who have failed up to four other therapies, new research shows....
Neurology

FDA OKs Botox for Upper Limb Spasticity in Children

Newsemia
Botox is the first neurotoxin to be approved in the US to treat upper limb spasticity for pediatric patients aged 2 years and older. FDA...
Neurology

FDA Approves First Vaccine for Dengue, With Restrictions

Newsemia
Dengvaxia is for the prevention of dengue disease caused by all dengue virus serotypes in people aged 9 to 16 years who have previously had...

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy